subgroup analysis

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits[...]

By afschroeder • August 13, 2025

JPEN Journal Club 87. The subgroup paradox

Koretz RL. JPEN Journal Club 87. The subgroup paradox. JPEN J Parenter Enteral Nutr. 2024 Sep 7. doi: 10.1002/jpen.2684. Epub ahead of print. PMID: 39243214.

By sjmartinez • September 8, 2024